CeQur®, a company specialising in medical devices for simplifying insulin delivery, has completed a £120 million funding round. This investment highlights strong support for the company’s goal to make diabetes management easier for individuals requiring multiple daily injections.

The funding will be used to support the expansion of CeQur Simplicity, the company’s innovative wearable insulin delivery device that provides discreet and injection-free insulin dosing for up to four days. CeQur plans to scale its sales and clinical teams, ensuring broader access to the device for people living with diabetes.

The company has reported increased use of CeQur Simplicity, with over 6,000 patients currently benefiting from its simple and convenient design for bolus insulin delivery.

CeQur is also enhancing pharmacy access to its products. Over two-thirds of commercially insured patients now have coverage for CeQur Simplicity, with agreements in place with Medicare Part-D and several State Medicaid programs. More than 80% of claims are covered under pharmacy benefits, and patients are paying, on average, less than £35 per month as a copay.

In manufacturing, CeQur’s newly built 40,000 sq/ft automated cleanroom facility completed its qualifications in late 2024. The facility is set to begin commercial production in 2025, supporting the company's growth plans.



Source: myceqursimplicity.com

Report Abuse